CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
तुलना करने के लिए मीट्रिक्स | 688185 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध688185पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −47.6x | −8.7x | −0.5x | |
PEG अनुपात | −0.55 | 0.34 | 0.00 | |
क़ीमत/बुक | 2.1x | 4.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 12.1x | 10.9x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 19.5% | 45.1% | 53.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | −11.9% | 8.9% | अनलॉक करें |